AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04340791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased proportion of lower energy density items
Description: The proportion of lower energy density vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (D and DL) (33% lower - 67% higher). Lower energy density items will be defined as lower energy density ≤ median of energy density distribution within a food category.
Study NCT04340791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labelling
Description: When energy density of an item ≤ median of ED distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions when logging-into the platform will introduce the badges to the participants: In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category.
Study NCT00134745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: estradiol
Description: tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
Study NCT00134745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol
Description: tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
Study NCT02407990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGB-A317
Description: In the dose escalation part, the dose levels were escalated following a modified 3+3 dose escalation scheme. In the scheduled exploration part, participants were assigned to doses and dose schedules. In the fixed dose exploration part, participants were assigned to dose group(s) not to exceed the maximum tolerated dose. In the dose expansion part, participants were assigned to different groups based on their tumor type.
Study NCT02407990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGB-A317
Description: Participants were assigned to different groups based on their tumor types
Study NCT02576301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1 - OXi4503
Description: Determination of MTD of OXi4503
Study NCT02576301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1 - OXi4503 + cytarabine
Description: Determination of MTD of the combination of OXi4503 + cytarabine
Study NCT02576301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2 - OXi4503 + cytarabine
Description: Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML
Study NCT02576301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 2 - OXi4503 + cytarabine
Description: Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
Study NCT03429829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flairesse varnish
Description: Flairesse is applied to enamel and dentine as protective varnish to prevent caries formation and to promote remineralization of initial caries. It is also used in the treatment of hypersensitive teeth by sealing dentin tubules and hypersensitive areas at the neck of the tooth and exposed root dentine. Flairesse varnish contains xylitol and fluoride (22,600 ppm). Both components have been well established for oral health by reducing caries prevalence and incidences.~During the application, children sat upright; their teeth were first cleaned and dried with cotton wool rolls. After mixing the fluoride varnish, it was applied as a thin layer to all surfaces of the lower and upper dentition, including proximal surfaces (using floss in case of tight contact points) as well as pits and fissures (using a small brush that was provided together with the varnish by the manufacturer). Children were advised not to drink or eat directly after the application, while this could not be controlled.
Study NCT00201786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
Study NCT00734097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Description: Once a day
Study NCT00734097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Exam
Description: every visit
Study NCT00734097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: every visit
Study NCT00734097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pregnancy test, if applicable
Description: as needed
Study NCT02511912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: V-Wave
Description: The V-Wave shunt implantation procedure is a standard femoral venous access and inter-atrial septal puncture intervention. The shunt is placed through the Fossa Ovalis.
Study NCT03929744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study NCT03929744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT03929744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally.
Study NCT03929744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally.
Study NCT03929744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally.
Study NCT03929744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Administered orally.
Study NCT03929744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.
Study NCT03929744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administered orally.
Study NCT01946763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre operative education
Description: Patients will be randomized in 2 groups (G1: educated, G2:non-educated) In the operating room and before starting anesthesia G1 will receive a pre operative education about anesthesia emergence, recovery and extubation.
Study NCT01946763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre operative education
Study NCT00484289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants \< 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants > 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
Study NCT01546636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypocapnic group
Description: Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
Study NCT01546636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normocapnic group
Description: Patients will be ventilated to an ETCO2 of 40-42 mm Hg
Study NCT03062579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible, without concurrent other immunosuppressive treatments.
Study NCT04386291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kundalini Yoga and Anxiety Reduction Training
Description: Daily practice of Kundalini Yoga (light stretching, breathing exercises, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
Study NCT04386291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation and Anxiety Reduction Training
Description: Daily practice of meditation (muscle relaxation, breathing, and meditation) guided by on-line video instruction, as well as the biweekly anxiety reduction psychoeducation.
Study NCT00192647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a
Description: PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.
Study NCT00192647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.
Study NCT04682444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enisamium Iodide
Description: Patients ingested Amizon tablets after meal without chewing as follows: 2 tablets (total dose 0.5 g) 3 times a day, for 7 days. Each tablet contains 0.25 g of Nmethyl- 4-N-methyl-4-benzylcarbamidopyridinium iodide (INN enisamium iodide).
Study NCT04682444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients ingested placebo tablets after meal without chewing in the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
Study NCT02992821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bed-side pocket size ultrasound imaging
Study NCT02992821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High frame rate tracking doppler
Study NCT01859273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: mHealth prototype system consisting of electronic medication tray, blood pressure cuff and smart phone
Study NCT02110615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care Practice Changes
Description: The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
Study NCT00697333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: restriction of radiotherapy to FDG-PET positive areas only
Description: Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose
Study NCT02687893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.
Study NCT02687893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (\~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
Study NCT02275832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 % Minoxidil lotion
Study NCT02275832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05589168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triage nurse
Description: Triage nurse joins 911 call
Study NCT05589168 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No triage nurse
Description: Triage nurse does not join 911 call (business as usual)
Study NCT03341767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: 50 or 100 mg micronized Clofazimine suspended in an oil-wax base in a gelatin capsule
Study NCT03341767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oil-wax in gelatin capsule
Study NCT04331587 — intervention group
Intervention type: DEVICE
Intervention: BF-P190 4 mm thin bronchoscope
Description: * EVIS EXERA III Bronchofiberviedoscopes~* Olympus
Study NCT04331587 — intervention group
Intervention type: DEVICE
Intervention: BF-MP190F 3 mm ultrathin bronchoscope
Description: * EVIS EXERA III Bronchofiberviedoscopes~* Olympus
Study NCT04331587 — intervention group
Intervention type: DEVICE
Intervention: Radial ultrasound probe (UM S20-17S)
Description: -Olympus
Study NCT04331587 — intervention group
Intervention type: DEVICE
Intervention: PeriView FLEX 21G Single Use Aspiration Needle
Description: * NA-403D-2021~* Gyrus ACMI, Inc.
Study NCT03636282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hockey FIT Program (Immediate Delivery)
Description: Hockey FIT is comprised of a 3-Month Active Phase and a 9-Month Minimally-Supported Phase.~Active Phase: 12 weekly, 90-minute group-based sessions consisting of classroom-based education and exercise. Outside of sessions, participants follow their individualized lifestyle prescriptions for healthy eating, physical activity (steps), and exercise. Participants are encouraged to regularly use health technology support tools customized to Hockey FIT. Minimally-supported phase: Participants are encouraged to continue with their healthy lifestyle behaviour changes and to regularly use the health technology support tools.
Study NCT03042897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo DASH diet
Study NCT03042897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo in aerobic exercise
Study NCT03042897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03042897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02043964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tears and cerebrospinal fluid sampling
Description: All patients recruited in this study will undergo a cerebrospinal fluid sampling which is an invasive procedure included in the actual routine practice. In addition a sampling from eyes will be obtain using the Schirmer test to get tears from the lacrimal gland.
Study NCT00959647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib was supplied in capsules.
Study NCT00959647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.
Study NCT00959647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration.
Study NCT00959647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a solution for intravenous administration.
Study NCT00538915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
Description: Nabi-IGIV 10% \[Immune Globulin Intravenous (Human), 10%\] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.
Study NCT00987246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Topical
Study NCT00987246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41005
Description: Topical
Study NCT00987246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS106521
Description: Topical
Study NCT04304768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent
Description: 0.5 ml prefilled syringe administrated intramuscularly
Study NCT02802306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tack Endovascular System
Description: Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System
Study NCT01432171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT01618799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Tablets 25 mg
Description: 2 x 25 mg tablet once a day
Study NCT00669994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Cipro XR 500 mg tablets taken once daily
Study NCT00626678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
Study NCT03939143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01(A), Sugamet SR Tab 5/1000mg®
Description: Period 1: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.
Study NCT03939143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugamet SR Tab 5/1000mg®, DA-1229_01(A)
Description: Period 1: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.
Study NCT00456846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: 100 mg/m\^2 ABI-007 weekly for 3 weeks followed by 1 week rest
Study NCT04922086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional aesthetic crown lengthening surgery
Description: The demarcation of the gingival zenith final position will be done on the teeth using a periodontal probe. This demarcation will be done through visual examination based on the crown length/width ratio and the position of the cemento-enamel junction (CEJ). The gingival margin of the central and canine incisors will be positioned at similar heights and a more coronal gingival contour will be determined for the lateral incisors. An internal bevel incision will be made with a blade on each tooth, preserving the interdental papillae. The incised gingival tissue will be removed using a periodontal curette in both groups. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). Carbide drills and manual chisels will be used for bone resection to obtained a CEJ-BC distance of 3 mm. Simple interproximal interrupted sutures will be performed.
Study NCT04922086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided dual aesthetic crown lengthening surgery
Description: The double guide will be positioned and an internal bevel incision on each tooth will be made following the guide demarcation. After the initial incision, the incised gingival tissue will be removed using a periodontal curette. An internal bevel incision will be made in the involved teeth and a full thickness flap will be displaced up to the the mucogingival junction level to expose the bone crest (BC). The dual guide will be positioned again and the bone tissue will be removed using carbide drills and manual chisels following the double guide. No interproximal crestal bone will be removed. Simple interproximal interrupted sutures will be performed to stabilize the flap.
Study NCT00626678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
Study NCT00626678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
Study NCT00626678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
Study NCT00421044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone/EPO906